104 related articles for article (PubMed ID: 8297100)
1. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.
Stewart DJ; Grewaal D; Green RM; Mikhael N; Goel R; Montpetit VA; Redmond MD
Anticancer Res; 1993; 13(6A):1945-52. PubMed ID: 8297100
[TBL] [Abstract][Full Text] [Related]
2. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
[TBL] [Abstract][Full Text] [Related]
3. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
5. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats.
Cusack BJ; Musser B; Gambliel H; Hadjokas NE; Olson RD
Cancer Chemother Pharmacol; 2003 Feb; 51(2):139-46. PubMed ID: 12647015
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
7. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.
Mushlin PS; Cusack BJ; Boucek RJ; Andrejuk T; Li X; Olson RD
Br J Pharmacol; 1993 Nov; 110(3):975-82. PubMed ID: 8298821
[TBL] [Abstract][Full Text] [Related]
8. HPLC quantification of doxorubicin in plasma and tissues of rats treated with doxorubicin loaded poly(alkylcyanoacrylate) nanoparticles.
Alhareth K; Vauthier C; Gueutin C; Ponchel G; Moussa F
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():128-32. PubMed ID: 22341684
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study.
Frost BM; Eksborg S; Björk O; Abrahamsson J; Behrendtz M; Castor A; Forestier E; Lönnerholm G
Med Pediatr Oncol; 2002 May; 38(5):329-37. PubMed ID: 11979457
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Cascegna S; Liberi G; Calafiore AM; Gianni L; Minotti G
J Pharmacol Exp Ther; 2006 Jul; 318(1):424-33. PubMed ID: 16614166
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
12. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients.
Morris RG; Reece PA; Dale BM; Green RM; Kotasek D; Saccoia NC; Sage RE
Ther Drug Monit; 1989; 11(4):380-3. PubMed ID: 2741185
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
14. Human autopsy tissue concentrations of mitoxantrone.
Stewart DJ; Green RM; Mikhael NZ; Montpetit V; Thibault M; Maroun JA
Cancer Treat Rep; 1986 Nov; 70(11):1255-61. PubMed ID: 3768871
[TBL] [Abstract][Full Text] [Related]
15. Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
de Bruijn P; Verweij J; Loos WJ; Kolker HJ; Planting AS; Nooter K; Stoter G; Sparreboom A
Anal Biochem; 1999 Jan; 266(2):216-21. PubMed ID: 9888978
[TBL] [Abstract][Full Text] [Related]
16. Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography.
Sakai-Kato K; Saito E; Ishikura K; Kawanishi T
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(19):1466-70. PubMed ID: 20392674
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).
Callies S; de Alwis DP; Wright JG; Sandler A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2003 Feb; 51(2):107-18. PubMed ID: 12647011
[TBL] [Abstract][Full Text] [Related]
18. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
19. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
20. Effect of doxorubicin on lipid peroxide levels in tissues of mice.
Sazuka Y; Yoshikawa K; Tanizawa H; Takino Y
Jpn J Cancer Res; 1987 Nov; 78(11):1281-6. PubMed ID: 3121563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
